Ro KhannaBuy
NKTR Common Stock · Transaction Sep 16, 2019 · Filed Oct 16, 2019 · Amount pending receipt enrichment
NASDAQ NMS - GLOBAL MARKET · NKTR
+0.45% · +$0.3300 · Vol 580.8K
After hours · updated 16:00:37 ET
Nektar Therapeutics
Pharmaceuticals
$73.09
Veridion Score
BETALOW CONF · 5/6 factorsWed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET · NKTR
MethodologyNKTR
Nektar Therapeutics
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
SELL BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
33/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is NKTR moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Nektar Therapeutics
PHARMACEUTICAL PREPARATIONSListed since
1994
Employees
63
Country
US
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$73.56
Day high
$74.23
Day low
$72.00
Previous close
$72.76
52W high
$100.35
-27.16% from high
52W low
$21.75
65% of range
Market cap
$2.5B
EPS
$-6.8800
Beta
1.04
Shares out
33.8M
Volume
580.8K
0.54× rel vol
Avg volume
1.1M
VWAP
$73.06
Price history computed in-house
1W
+3.41%
1M
-0.08%
3M
-12.33%
1Y
+223.98%
YTD
+72.87%
SMA 50 $65.89 · above
SMA 200 $63.17 · above
52W position 65%
NKTR overview
Veridion Score
33
5 of 6 factors measured
Congress receipts
5
Ro Khanna · Purchase
13F holders
None on file
Related filings and maps
Public disclosures
Congress activity in NKTR
Official filing ↗
Ro KhannaSell
NKTR Common Stock · Transaction Jun 5, 2019 · Filed Jul 11, 2019 · Amount pending receipt enrichment
Ro KhannaBuy
NKTR Common Stock · Transaction Jun 3, 2019 · Filed Jul 11, 2019 · Amount pending receipt enrichment
Nektar Therapeutics · Transaction Jun 21, 2018 · Filed Oct 2, 2018 · $1,001 to $15,000
Nektar Therapeutics · Transaction Jun 6, 2018 · Filed Oct 2, 2018 · $1,001 to $15,000
Federal contracts
NKTR contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NKTR in this window.
Lobbying spend
NKTR lobbying filings, year to date.
Registered lobbying filings matched to Nektar Therapeutics.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NKTR in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for NKTR.
Options
Sovereign unlock shows live options positioning for NKTR.